Cite
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
MLA
Naranbhai, Vivek, et al. “HLA-A*03 and Response to Immune Checkpoint Blockade in Cancer: An Epidemiological Biomarker Study.” Lancet Oncology, vol. 23, no. 1, Jan. 2022, pp. 172–84. EBSCOhost, https://doi.org/10.1016/S1470-2045(21)00582-9.
APA
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, 23(1), 172–184. https://doi.org/10.1016/S1470-2045(21)00582-9
Chicago
Naranbhai, Vivek, Mathias Viard, Michael Dean, Stefan Groha, David A Braun, Chris Labaki, Sachet A Shukla, et al. 2022. “HLA-A*03 and Response to Immune Checkpoint Blockade in Cancer: An Epidemiological Biomarker Study.” Lancet Oncology 23 (1): 172–84. doi:10.1016/S1470-2045(21)00582-9.